Valuation: Biogen Inc.

Market Cap 33.63B 175B 29.51B 27.87B 25.4B 47.54B 3,223B 47.88B 334B 129B 1,647B 126B 124B 5,292B P/E 2026 *
37.1x
P/E 2027 * 20.1x
Enterprise Value 38.57B 201B 33.84B 31.96B 29.13B 54.52B 3,696B 54.91B 382B 148B 1,888B 145B 142B 6,069B EV / Sales 2026 *
3.69x
EV / Sales 2027 * 3.38x
Free-Float
85.8%
Yield 2026 *
-
Yield 2027 * -
1 day+0.42%
1 week+0.42%
Current month-0.01%
1 month-0.01%
3 months+16.16%
6 months+17.56%
Current year+16.94%
1 month 187.5
Extreme 187.5
188.28
Current year 147.5
Extreme 147.5
191
1 year 121.32
Extreme 121.32
191
3 years 110.07
Extreme 110.07
225
5 years 110.07
Extreme 110.07
277
10 years 110.07
Extreme 110.07
360
Manager TitleAgeSince
Chief Executive Officer 66 2022-11-13
Director of Finance/CFO 60 2025-02-28
Chief Tech/Sci/R&D Officer - 2024-10-27
Director TitleAgeSince
Director/Board Member 69 2010-03-22
Director/Board Member 77 2009-12-31
Director/Board Member 72 2019-06-18
Change 5-day change 1-year change 3-year change Capi.($)
+0.42%+0.42% - - 33.63B
+2.08%+29.11%+712.09%+100.00% 79.4B
-1.00%+0.41%+39.75%-5.35% 78.69B
+2.80%+2.02%-8.59%-27.82% 59.52B
-0.42%+0.66%-6.20%+174.07% 46.58B
-1.80%-2.29%-11.16%+30.46% 46.53B
+0.55%+5.61%+65.68%-11.62% 33.63B
-0.44%-1.13%+49.81%+109.59% 25.11B
-3.56%-6.10%+2.72%+140.98% 22.13B
-0.09%-1.62%+56.19%+95.70% 15.31B
Average -0.63%+4.05%+100.03%+67.33% 45.21B
Weighted average by Cap. -0.67%+6.45%+154.16%+54.89%

Financials

2026 *2027 *
Net sales 10.44B 54.3B 9.16B 8.66B 7.89B 14.77B 1,001B 14.87B 104B 40.12B 511B 39.21B 38.36B 1,644B 10.66B 55.42B 9.35B 8.83B 8.05B 15.07B 1,021B 15.18B 106B 40.94B 522B 40.02B 39.15B 1,677B
Net income 997M 5.18B 875M 826M 753M 1.41B 95.54B 1.42B 9.89B 3.83B 48.81B 3.74B 3.66B 157B 1.86B 9.67B 1.63B 1.54B 1.4B 2.63B 178B 2.65B 18.43B 7.14B 91.02B 6.98B 6.83B 293B
Net Debt 4.94B 25.67B 4.33B 4.09B 3.73B 6.98B 473B 7.03B 48.96B 18.96B 242B 18.54B 18.13B 777B 2.42B 12.58B 2.12B 2.01B 1.83B 3.42B 232B 3.45B 24B 9.3B 118B 9.09B 8.89B 381B
Logo Biogen Inc.
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows: - sales of medicines (72%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.; - royalties (7.4%) ; - other (20.6%): primarily revenues from partnership agreements.
Employees
7,500
Date Price Change Volume
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
35
Last Close Price
227.60USD
Average target price
238.18USD
Spread / Average Target
+4.65%

Quarterly revenue - Rate of surprise